89Bio

89bio CMO touts advantages of pegozafermin following Phase III initiation
Clinical Trials Arena
Thu, 05/23/24 - 11:22 am
89Bio
pegozafermin
MASH
NASH
clinical trials
5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffra
BioSpace
Mon, 04/15/24 - 11:24 am
MASH
NASH
Madrigal Pharmaceuticals
Rezdiffra
Ionis Pharmaceuticals
ION224
Altimmune
pemvidutid
89Bio
pegozafermin
Viking Therapeutics
VK2809
Aligos Therapeutics
ALG-055009
89bio wins EMA priority status for MASH candidate pegozafermin
Clinical Trials Arena
Thu, 03/28/24 - 11:21 am
89Bio
Europe
EMA
pegozafermin
MASH
89bio kicks off Phase III trial for pegozafermin in MASH
Clinical Trials Arena
Tue, 03/12/24 - 06:51 pm
89Bio
clinical trials
pegozafermin
MASH
NASH
89bio Unveils Bullish Long-Term Data for NASH Candidate
BioSpace
Tue, 11/28/23 - 10:21 am
89Bio
NASH
clinical trials
pegozafermin
EASL 2023 – Biomarkers back a new NASH player
EP Vantage
Mon, 06/26/23 - 09:32 am
NASH
89Bio
pefozafermin
Boston Pharmaceuticals
BOS-580
Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio
Fierce Biotech
Wed, 06/21/23 - 10:51 am
Boston Pharmaceuticals
NASH
Novartis
Akero Therapeutics
89Bio
BOS-580
89Bio Enlivened by Nash success
EP Vantage
Thu, 03/23/23 - 09:50 am
89Bio
NASH
Akero Therapeutics
pegozafermin
INTERCEPT
Madrigal Pharmaceuticals
89bio’s PhII data add to quick succession of NASH readouts as field seeks turnaround
Endpoints
Wed, 03/22/23 - 10:05 am
89Bio
NASH
clinical trials
gozafermin
Akero Therapeutics
Spotlight – What is next in Nash
EP Vantage
Fri, 03/3/23 - 10:02 am
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
89bio to initiate Phase III trials for pegozafermin in severe hypertriglyceridaemia
Clinical Trials Arena
Wed, 01/11/23 - 10:47 am
89Bio
pegozafermin
clinical trials
hypertriglyceridemia
Catalysts ahead for the smaller players
EP Vantage
Wed, 12/21/22 - 11:19 am
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
89bio’s home run fails to excite
EP Vantage
Wed, 06/29/22 - 10:35 am
89Bio
NASH
pegozafermin
hypertriglyceridemia
89bio gains a little more confidence in NASH treatment with new hormone data
Fierce Biotech
Sun, 03/27/22 - 03:52 pm
89Bio
NASH
liver disease
pegozafermin
Teva spinout delays NASH IPO while Galera prices below range
Endpoints
Thu, 11/7/19 - 10:24 am
Teva Pharmaceutical
89Bio
Galera
IPOs
Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile stumbles
Endpoints
Mon, 10/14/19 - 09:58 am
IPOs
Galera Therapeutics
89Bio
Centogene
89Bio starting Proof of Concept Trial for NASH therapy and announcing expansion of leadership team
CP WIre
Fri, 08/9/19 - 08:11 pm
89Bio
NASH
NAFLD
clinical trials
89Bio starting Proof of Concept Trial for NASH therapy and announcing expansion of leadership team
Fri, 08/9/19 - 08:10 pm
89Bio
NASH
NAFLD
clinical trials
89Bio Joins NASH Chase with a Teva Drug and $60M in Funding
Xconomy
Thu, 10/25/18 - 11:19 pm
89Bio
Teva Pharmaceutical
NASH